Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer
Article first published online: 10 APR 2007
International Journal of Urology
Volume 14, Issue 3, pages 264–267, March 2007
How to Cite
Nishimura, K., Arichi, N., Tokugawa, S., Yoshioka, I., Kishikawa, H. and Ichikawa, Y. (2007), Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. International Journal of Urology, 14: 264–267. doi: 10.1111/j.1442-2042.2007.01681.x
- Issue published online: 10 APR 2007
- Article first published online: 10 APR 2007
- Received 20 June 2006; accepted 14 September 2006.
- hormone refractory prostate cancer;
- maximum androgen blockade (MAB);
- second-line agent
Abstract: We analyzed clinical effects of flutamide as a second-line agent for maximum androgen blockade (MAB) in patients with relapsing prostate cancer who received bicalutamide as the first-line MAB agent. This study included 13 patients with progressive prostate cancer who had relapsed after first-line MAB, with bicalutamide at 80 mg/day. After checking for antiandrogen withdrawal syndrome, they were given flutamide at 375 mg/day as second-line MAB. The effectiveness of that therapy was evaluated by changes in prostatic specific antigen (PSA) levels, with response defined as a decrease of greater than 50% from the start of therapy. We also compared several factors between responders and non-responders. Nine (69.2%) of the 13 patients showed a decrease in PSA levels, of whom five (38.5%) had a greater than 50% decrease and were defined as responders. The median duration of PSA response was 11.0 months (range 5–20 months). Patients who had a longer duration of response to first-line MAB had a significantly greater response to second-line MAB. For advanced prostate cancer patients who progressed on first-line MAB with bicalutamide, flutamide administration as a second-line antiandrogen was found to be relatively effective, especially for those who showed a longer duration of response to the first-line MAB. Our results confirm previous findings that MAB using flutamide is an effective second-line hormonal therapy.